NeOnc Technologies Holdings Inc... Show more
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for intracranial malignancies and central nervous system conditions. Its proprietary NEO drug-development platform is designed to address the persistent challenge of crossing the blood-brain barrier, with patent protections extending to 2038.
The company's lead candidates include NEO100, an intranasal form of perillyl alcohol in Phase II clinical development, and NEO212, an oral conjugate of perillyl alcohol and temozolomide in Phase I/II trials. Both programs target brain cancers such as glioblastoma and meningioma and carry FDA Fast-Track and Investigational New Drug (IND) status. NeOnc licenses an extensive patent portfolio from the University of Southern California and generates minimal revenue, relying instead on equity and debt financing to fund its clinical programs.
Over the last 30 days, NTHI advanced approximately 12%, moving from a closing price near $2.90 in mid-October to roughly $3.26. The climb was not linear: shares consolidated in the low-$3.00 range through late October before surging to an intraday peak above $5.40 in mid-November, only to pull back sharply in the most recent sessions.
The picture is different over the last quarter. From a level near $4.56 in mid-August, the stock has declined roughly 29% as of the latest reading. That three-month stretch included a summer volatility spike, a prolonged slide to a low near $2.50 in early October, and the November recovery that remains well below the quarter's highs.
The November rally coincided with a cluster of clinical and corporate developments. NeOnc secured a Type B End-of-Phase meeting with the U.S. Food and Drug Administration for its intranasal NEO100 program, scheduled for early January 2027, a step investors interpreted as progress toward a potential Phase 3 trial.
Around the same time, the company announced plans to present findings from two brain-cancer drug programs at the Society for Neuro-Oncology annual meeting, and Chief Executive Officer Amir Heshmatpour disclosed additional open-market share purchases below $5, extending a pattern of insider buying. These catalysts helped lift shares from about $3.07 in early November to a closing high near $4.91.
The subsequent pullback reflects the stock's characteristic volatility, with profit-taking following the rapid advance. The company's third-quarter earnings release in early November also underscored its limited revenue and ongoing operating losses, factors that continue to weigh on sentiment during pullbacks.
The broader three-month trend has been shaped by the financial realities of a pre-revenue biotech. NeOnc's filings have disclosed a going-concern warning, minimal cash reserves, and reliance on dilutive financing to fund operations. A 1-for-6 reverse stock split completed in April 2026 and a series of capital raises have contributed to share-price pressure and volatility.
After an August spike to the mid-$5 range, shares drifted lower through September and October as investors weighed liquidity risks against the promise of the clinical pipeline. The November recovery, led by the FDA meeting milestone and insider buying, marks a partial reversal but leaves the stock below its early-quarter levels.
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a platform that offers hundreds of AI-driven bots trading thousands of tickers. Only the top-performing and most relevant robots appear in this section, giving users a focused view of strategies that have recently demonstrated strength. The bots vary widely in approach, timeframe, and performance metrics, so investors can compare different styles rather than relying on a single method. For those interested in systematic, rules-based trading tools, the page provides a useful starting point for exploration.
Several catalysts will likely shape NTHI's trajectory in the months ahead. The Type B End-of-Phase meeting with the FDA in early January 2027 for NEO100 is a key milestone, as its outcome could clarify the path toward a Phase 3 trial. Data presentations at the Society for Neuro-Oncology meeting and updates on the NEO212 program also carry the potential to move the stock.
Investors should also monitor the company's liquidity position and any additional financing activity, given its going-concern disclosure and minimal cash reserves. Broader biotech sentiment, regulatory decisions, and clinical enrollment progress remain important variables. As with all clinical-stage companies, the timing and results of trials introduce significant uncertainty, and outcomes are not guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for NTHI moved out of overbought territory on November 17, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 instances where the indicator moved out of the overbought zone. In 4 of the 4 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 14 cases where NTHI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
NTHI broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NTHI as a result. In 23 of 26 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for NTHI just turned positive on October 16, 2026. Looking at past instances where NTHI's MACD turned positive, the stock continued to rise in 9 of 11 cases over the following month. The odds of a continued upward trend are 82%.
NTHI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NTHI crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +8.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTHI advanced for three days, in 67 of 77 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 39 of 41 cases where NTHI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. NTHI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.425) is normal, around the industry mean (3.596). P/E Ratio (-1.646) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1666.667) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTHI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology